Three trials funded GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

CIHR SUCCESS with 7.5 million for three trials: GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.

More >>
 

Matching ExCELLirate Canada funding from The Ontario Research Fund

It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".

More >>
 

CCTG at ASCO 2022

CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago

More >>
 

CCTG MA32 trial was published recently in the Journal of the American Medical Association

The findings of the CCTG MA32 trial were published recently in the Journal of the American Medical Association. According to the study results, a widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most common forms of the disease.

More >>
 

Planned trials

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

ALC7

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

CRC10

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

EN11

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

More >>

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

HD12

PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

More >>

HN13

Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

MA32R

Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer

MA41

De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)

ME16

Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma

NE1

NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

More >>

PR23

Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy

PR24

Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

SC28

The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

I242A

A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

Recently activated

BLC5

MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

More >>

MEC6

Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma

More >>

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
 
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

Endocrine-Related Cancer 29: 335 - 344, 2022
Kulke MH;Ou FS;Niedzwiecki D;Huebner L;Kunz P;Kennecke HF;Wolin EM;Chan JA;O'Reilly EM;Meyerhardt JA;Venook A;

More >>

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Cancers 14: 2985, 2022
Manji A;Samson Y;Deyell RJ;Johnston DL;Lewis VA;Zorzi AP;Berman JN;Brodeur-Robb K;Morrison E;Kee L;Kumar S;Baruchel S;Whitlock JA;Morgenstern DA;

More >>

Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

, 2022
Allaf M;Kim SE;Harshman LC;McDermott DF;Master VA;Signoretti S;Cole S;Moon H;Adra N;Singer EA;Gills J;Choueiri TK;Leibovich B;Michaelson MD;Shuch B;Lara PN;Heng DYC;Kapoor A;Carducci MA;Haas NB;

More >>

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial (ONLINE)

JAMA Oncology , 2022
Conroy T;Castan F;Lopez A;Turpin A;Ben Abdelghani M;Wei AC;Mitry E;Biagi JJ;Evesque L;Artru P;Lecomte T;Assenat E;Bauguion L;Ychou M;Bouche O;Monard L;Lambert A;Hammel P;Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group;

More >>

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results (ONLINE)

J Clin Oncol : JCO, 2022
Kennecke HF;O'Callaghan CJ;Loree JM;Moloo H;Auer R;Jonker DJ;Raval M;Musselman R;Ma G;Caycedo-Marulanda A;Simianu VV;Patel S;Pitre LD;Helewa R;Gordon VL;Neumann K;Nimeiri H;Sherry M;Tu D;Brown CJ;

More >>